Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

26 March 2026

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights Reports Full Year 2025 Financial Results and Business Highlights
24 March 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer The study expected to enroll approximately 1,800 patients with resectable HER2-positive BC
20 March 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016 This milestone brings another innovative bispecific ADC from the company's pipeline into pivotal development
18 March 2026

Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer Mr. Wang’s joining will further enhance the company’s core competitiveness in the capital markets and deliver greater long-term value to shareholders
17 March 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027 JSKN027 is the company’s fifth ADC candidate entering clinical development, as well as the world's first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials
13 March 2026

Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE JSKN021 showed stronger tumor inhibition efficacy than mono payload ADCs in multiple CDX models
11 March 2026

Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer Dr. Wang's joining will accelerate the global development and commercialization of the company's innovative product pipeline
14 February 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003 is expected to provide patients with a new therapeutic option
04 February 2026

World Cancer Day | People-Centered Innovation Lighting the Way for Hope People-Centered, United Against Cancer
27 Janurary 2026

Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology the positive results robustly demonstrate that anbenitamab combined with chemotherapy has the potential to become a new standard of care for patients with HER2-positive gastric cancer who have failed ...